198
Views
8
CrossRef citations to date
0
Altmetric
Research Article

Effect of very early treatment in rheumatoid arthritis on bone oedema and synovitis, using magnetic resonance imaging

, , , , &
Pages 339-344 | Accepted 09 Feb 2012, Published online: 31 May 2012

References

  • Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev 2005;4:130–6.
  • Narváez JA, Narváez J, De Lama E, De Albert M. MR imaging of early rheumatoid arthritis. Radiographics 2010;30:143–63.
  • Klarlund M, Ostergaard M, Jensen KE, Madsen JL, Skjødt H, Lorenzen I. Magnetic resonance imaging, radiography, and scintigraphy of the finger joints: one year follow up of patients with early arthritis. The TIRA Group. Ann Rheum Dis 2000;59:521–8.
  • McQueen FM, Stewart N, Crabbe J, Robinson E, Yeoman S, Tan PL, . Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosions at four months after symptom onset. Ann Rheum Dis 1998;57:350–6.
  • Ostergaard M, Hansen M, Stoltenberg M, Gideon P, Klarlund M, Jensen KE, . Magnetic resonance imaging-determined synovial membrane volume as a marker of disease activity and a predictor of progressive joint destruction in the wrists of patients with rheumatoid arthritis. Arthritis Rheum 1999;42:918–29.
  • McGonagle D, Conaghan PG, O’Connor P, Gibbon W, Green M, Wakefield R, . The relationship between synovitis and bone changes in early untreated rheumatoid arthritis: a controlled magnetic resonance imaging study. Arthritis Rheum 1999;42:1706–11.
  • Haavardsholm EA, Bøyesen P, Østergaard M, Schildvold A, Kvien TK. Magnetic resonance imaging findings in 84 patients with early rheumatoid arthritis: bone marrow oedema predicts erosive progression. Ann Rheum Dis 2008;67:794–800
  • McQueen FM, Benton N, Perry D, Crabbe J, Robinson E, Yeoman S, . Bone edema scored on magnetic resonance imaging scans of the dominant carpus at presentation predicts radiographic joint damage of the hands and feet six years later in patients with rheumatoid arthritis. Arthritis Rheum 2003;48:1814–27.
  • Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2004;43: 906–14.
  • van der Heide A, Jacobs JW, Bijlsma JW, Heurkens AH, van Booma-Frankfort C, van der Veen MJ, . The effectiveness of early treatment with ‘second-line’ antirheumatic drugs. A randomized, controlled trial. Ann Intern Med 1996;124:699–707.
  • Lard LR, Visser H, Speyer I, vander Horst-Bruinsma IE, Zwinderman AH, Breedveld FC, . Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001;111:446–51.
  • Boers M. Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis Rheum 2003;48:1771–4.
  • Quinn MA, Emery P. Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin Exp Rheumatol 2003;21:S154–7.
  • Quinn MA, Conaghan PG, O’Connor PJ, Karim Z, Greenstein A, Brown A, . Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:27–35.
  • Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, . The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26–37.
  • Durez P, Malghem J, Nzeusseu Toukap A, Depresseux G, Lauwerys BR, Westhovens R, . Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. Arthritis Rheum 2007;56:3919–27.
  • Zikou AK, Argyropoulou MI, Voulgari PV, Xydis VG, Nikas SN, Efremidis SC, . Magnetic resonance imaging quantification of hand synovitis in patients with rheumatoid arthritis treated with adalimumab. J Rheumatol 2006;33:219–23.
  • Argyropoulou MI, Glatzouni A, Voulgari PV, Xydis VG, Nikas SN, Efremidis SC, . Magnetic resonance imaging quantification of hand synovitis in patients with rheumatoid arthritis treated with infliximab. Joint Bone Spine 2005;72:557–61.
  • Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, . 2010 Rheumatoid arthritis classification criteria. An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62: 2569–81.
  • Prevoo ML, van ‘t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.
  • Ejbjerg B, McQueen F, Lassere M, Haavardsholm E, Conaghan P, O’Connor P, . The EULAR-OMERACT rheumatoid arthritis MRI reference image atlas: the wrist joint. Ann Rheum Dis 2005; 64(Suppl 1):i23–47.
  • Conaghan P, Bird P, Ejbjerg B, O’Connor P, Peterfy C, McQueen F, . The EULAR-OMERACT rheumatoid arthritis MRI reference image atlas: the metacarpophalangeal joints. Ann Rheum Dis 2005;64(Suppl 1):i11–21.
  • Østergaard M, Edmonds J, McQueen F, Peterfy C, Lassere M, Ejbjerg B, . An introduction to the EULAR-OMERACT rheumatoid arthritis MRI reference image atlas. Ann Rheum Dis 2005;64(Suppl 1):i3–7.
  • Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, . Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309–18.
  • Kuriya B, Arkema EV, Bykerk VP, Keystone EC. Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis: a meta-analysis of clinical and radiographic remission. Ann Rheum Dis 2010;69:1298–304.
  • Finckh A, Liang MH, van Herckenrode CM, de Pablo P. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis. Arthritis Rheum 2006;55:864–72.
  • Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, . EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964–75.
  • Jimenez-Boj E, Nobauer-Huhmann I, Hanslik-Schnabel B, Dorotka R, Wanivenhaus AH, Kainberger F, . Bone erosions and bone marrow edema as defined by magnetic resonance imaging reflect true bone marrow inflammation in rheumatoid arthritis. Arthritis Rheum 2007;56:1118–24.
  • McQueen FM, Gao A, Ostergaard M, King A, Shalley G, Robinson E, . High-grade MRI bone oedema is common within the surgical field in rheumatoid arthritis patients undergoing joint replacement and is associated with osteitis in subchondral bone. Ann Rheum Dis 2007;66:1581–7.
  • McQueen FM, Ostendorf B. What is MRI bone oedema in rheumatoid arthritis and why does it matter? Arthritis Res Ther 2006;8:222.
  • Kosta PE, Voulgari PV, Zikou AK, Drosos AA, Argyropoulou MI. The usefulness of magnetic resonance imaging of the hand and wrist in very early rheumatoid arthritis. Arthritis Res Ther 2011;13:R84.
  • Hetland ML, Ejbjerg B, Hørslev-Petersen K, Jacobsen S, Vestergaard A, Jurik AG, . MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA). Ann Rheum Dis 2009;68:384–90.
  • Saleem B, Brown AK, Keen H, Nizam S, Freeston J, Karim Z, . Disease remission state in patients treated with the combination of tumor necrosis factor blockade and methotrexate or with disease-modifying antirheumatic drugs: a clinical and imaging comparative study. Arthritis Rheum 2009; 60:1915–22.
  • Gandjbakhch F, Conaghan PG, Ejbjerg B, Haavardsholm EA, Foltz V, Brown AK, . Synovitis and osteitis are very frequent in rheumatoid arthritis clinical remission: results from an MRI study of 294 patients in clinical remission or low disease activity state. J Rheumatol 2011;38:2039–44.
  • Brown AK, Conaghan PG, Karim Z, Quinn MA, Ikeda K, Peterfy CG, . An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum 2008;58:2958–67.
  • Papadopoulos NG, Alamanos Y, Papadopoulos IA, Tsifetaki N, Voulgari PV, Drosos AA. Disease modifying antirheumatic drugs in early rheumatoid arthritis: a longterm observational study. J Rheumatol 2002;29:261–6.
  • Drosos AA, Karantanas AH, Psychos D, Tsampoulas C, Moutsopoulos HM. Can treatment with methotrexate influence the radiological progression of rheumatoid arthritis? Clin Rheumatol 1990;9:342–5.
  • Braun J, Rau R. An update on methotrexate. Curr Opin Rheumatol 2009;21:216–23.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.